Wedbush Issues Positive Forecast for KNSA Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Investment analysts at Wedbush upped their Q1 2025 EPS estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Monday, January 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of $0.10 for the quarter, up from their previous estimate of $0.09. Wedbush currently has a “Outperform” rating and a $34.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.15 EPS and FY2025 earnings at $0.56 EPS.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. increased their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Evercore ISI raised their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Trading Up 2.6 %

Shares of NASDAQ KNSA opened at $18.82 on Thursday. Kiniksa Pharmaceuticals has a 12-month low of $16.56 and a 12-month high of $28.15. The business’s fifty day simple moving average is $20.94 and its 200-day simple moving average is $23.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million during the quarter, compared to analysts’ expectations of $111.51 million. During the same period in the prior year, the business earned ($0.20) EPS. The business’s quarterly revenue was up 67.4% on a year-over-year basis.

Insider Activity

In related news, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the transaction, the chief operating officer now directly owns 88,975 shares in the company, valued at approximately $1,622,904. The trade was a 13.60 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 24,092 shares of company stock worth $471,609. 54.57% of the stock is currently owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in KNSA. Hennion & Walsh Asset Management Inc. increased its position in Kiniksa Pharmaceuticals by 1.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company’s stock worth $3,947,000 after buying an additional 3,673 shares during the period. Nordea Investment Management AB grew its position in shares of Kiniksa Pharmaceuticals by 4.4% during the fourth quarter. Nordea Investment Management AB now owns 194,883 shares of the company’s stock worth $3,818,000 after acquiring an additional 8,257 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $4,997,000. Franklin Resources Inc. increased its holdings in shares of Kiniksa Pharmaceuticals by 1.7% in the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock valued at $1,798,000 after acquiring an additional 1,100 shares during the period. Finally, XTX Topco Ltd raised its position in Kiniksa Pharmaceuticals by 62.2% in the 3rd quarter. XTX Topco Ltd now owns 27,302 shares of the company’s stock valued at $682,000 after purchasing an additional 10,474 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.